Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet.
Epstein-Barr virus (EBV)-associated lymphoproliferative disorders frequently develop in patients with acquired immunodeficiency syndrome (AIDS). The lymphoproliferative disorders are usually treated with a combination of cytotoxic drugs, and virustatic medication is thought to be ineffective. However, we report about two AIDS patients with EBV-associated lymphoproliferative disorders not responding to a standard chemotherapy, who achieved complete tumour regression after virustatic therapy with foscarnet.
Schneider
U
U
Charité Campus Virchow-Klinikum der Humboldt Universität, Dept of Medicine, Berlin, Germany.
Ruhnke
M
M
Delecluse
H J
HJ
Stein
H
H
Huhn
D
D
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D017245:Foscarnet / Q000627:therapeutic use*; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy; D008232:Lymphoproliferative Disorders / Q000821:virology*; D008297:Male; D008875:Middle Aged
D000998:Antiviral Agents; D017245:Foscarnet